Share Name Share Symbol Market Type Share ISIN Share Description
Midatech Pharma LSE:MTPH London Ordinary Share GB00BRTL9B63 ORD 0.005P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.15p -2.61% 5.60p 269,165 14:56:48
Bid Price Offer Price High Price Low Price Open Price
5.50p 5.70p 5.75p 5.60p 5.75p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.76 -17.33 -31.00 22.9

Midatech Pharma (MTPH) Latest News

More Midatech Pharma News
Midatech Pharma Takeover Rumours

Midatech Pharma (MTPH) Share Charts

1 Year Midatech Pharma Chart

1 Year Midatech Pharma Chart

1 Month Midatech Pharma Chart

1 Month Midatech Pharma Chart

Intraday Midatech Pharma Chart

Intraday Midatech Pharma Chart

Midatech Pharma (MTPH) Discussions and Chat

Midatech Pharma Forums and Chat

Date Time Title Posts
18/3/201921:27Midatech Pharma (MTPH) sees 10-fold increase504
23/1/201913:25Midatech Pharma (MTPH) One to Watch 1
03/1/201712:41Midatech Pharma PLC181
10/8/201607:55MTPH-

Add a New Thread

Midatech Pharma (MTPH) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
16:15:585.603,125175.00O
14:56:385.5010,000550.20O
14:55:545.5512,498693.64O
14:11:315.6036,8292,062.42O
12:53:075.601,56287.47O
View all Midatech Pharma trades in real-time

Midatech Pharma (MTPH) Top Chat Posts

DateSubject
19/3/2019
08:20
Midatech Pharma Daily Update: Midatech Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker MTPH. The last closing price for Midatech Pharma was 5.75p.
Midatech Pharma has a 4 week average price of 3.50p and a 12 week average price of 2.55p.
The 1 year high share price is 49p while the 1 year low share price is currently 2.55p.
There are currently 409,399,613 shares in issue and the average daily traded volume is 3,734,433 shares. The market capitalisation of Midatech Pharma is £22,926,378.33.
18/3/2019
20:38
mam fach: Looks like MTP is coming down to align with MTPH. Was hoping the reverse might happen. Probably know next few weeks which way share price is going.
02/3/2019
14:06
nerdofsteel: It appears there may have been a stress / forced seller last week which may explain the share price movement. If cleared it could rise from here. hxxps://www.cityfinancial.co.uk/assets/download/15013/City%20Financial%20Investment%20Fund%20Series%20IV%20-%20Reports%20and%20accounts%20(interim)%20-%202018%2010.pdf
28/2/2019
14:55
pilkersa: Share price action here is really incomprehensible. Think I will hold for a while. At least sar is starting to look up....
28/2/2019
11:26
mam fach: Lower price seems to be bringing in fresh buyers. Hope I was lucky to have top up @ under 7.5p. Won't know till later. No idea where share price is going.
10/1/2019
10:02
tomboyb: To me this looks like going 7p+ pretty soon - hxxp://www.midatechpharma.com/share-price-information NASDAQ value -
01/9/2018
03:55
jamtomorrow2: You said it. It’s not bioequivalent - but it is potentially better. The problem is that you will have to prove that to the FDA in a large Phase 3 trial. That’s going to cost time and big money, which Midatech doesn’t have. It will therefore need to partner the product and take upfronts and royalties as opposed to keeping 100% control of the product and selling it through Dara. The mathematics of all this are far from straightforward hence the modest share price reaction.
22/2/2018
06:58
jamtomorrow2: Another new low. Those peak sales forecasts for both MTD201 and the brain cancer drug look pure fantasy to me. Sandostatin is not patent protected anymore and it looks like three generics will be on the market before MTD201 is launched in 2020. The price by that time will be way lower than now - something that the forecasts haven’t taken into account. Also the brain cancer drug has such a limited market that I have no idea how they have arrived at their figures. Bearing in mind that DARA seems to be incapable of marketing its existing drugs it’s very hard to fathom how they will be capable of selling 10-15 times the current sales level. Also what happens to the recently negotiated loan if MTD201 fails to achieve bioequivalence? We haven’t been told the terms and conditions attached to the loan but one would assume that it would be subject to meeting certain drug development goals and surely MTD201 bioequivalence is one of those goals. Would the loan then have to be repaid quickly leaving MTPH in desperate need of new cash just as the share price crashes further? Continous delays and a plethora of unanswered questions surround this company.
16/1/2018
23:04
jamtomorrow2: The share price is 45p for a reason. One failed trial, a loss making acquisition and two approvals to conduct a trial after 3 years as a public company. That’s all folks. But at least one shareholder seems happy.
09/1/2018
23:02
jamtomorrow2: MTD201 study approved!! Somewhat misleading headline! I was under the impression that it had been approved to commence ages ago. Nobody ever said the hold-up was due to not having EU approval. So the previously quoted reason for the hold-up of problems relating to gearing up to production levels at the Spanish lab was basically as misleading as the heading to today’s announcement. So when is this wretched trial actually going to start? It’s delay after delay after delay. No wonder the share price is so bombed out. Also why do we hear nothing about the success or otherwise of the compansionate UK program re childrens brain cancer? This had been going on for a couple of years now. If successful you’d have thought they’d be singing out the good news from the rooftops.
30/12/2015
09:57
hutch_pod: Did you see this from 17th? hTtp://seekingalpha.com/author/bart-van-velzen/comments High time for an update on this article: the merger has been approved, the ADR's have been issued, but the idea so far hasn't worked out like I had planned. One of the risks highlighted in the article was: "Midatech's ADRs trading in tandem with its Ordinary Shares could cause the price of the ADRs to go up, but the same mechanism could obviously also cause the price of the Ordinary Shares in the UK to go down." Unfortunately, this is what happened. Since the deal was completed the MTPH share price in London took a bath and has now dropped close to 25% in about two weeks, making this deal a nightmare for the UK holders. I indicated in the article MTPH was illiquid and unshortable; I knew the shares in London would likely drop as a result of ADR-holders converting and selling, explaining some of the premium to the US price. But I hadn't expected an <20M take over to cause MTPH to shed >30M in market cap which in itself is of course fundamentally questionable; Midatech + DARA combined is now worth less than Midatech itself used to do. Also, trading volumes were horrendously low. I had expected MTPH-management, or any of its many experienced institutional investors, to see this coming based on the illiquidity of MTPH-shares, and to have at least something of contingency plan ready. Apparently so far they didn't. One would assume experienced investors like Neil Woodford (who holds an 18% stake through Woodford Investment Management) would not allow his fund to lose millions in a few days on trading volumes of about 40K $ without stepping in. One would also assume he, or any one of the other holders being hung out to dry, still will. It wouldn't take much. Anyway, with regards to ADR conversion: no US listed ADR I'm aware of trades at a discount to its UK listed peers, and MTP won't either in the mid term
Midatech Pharma share price data is direct from the London Stock Exchange
Your Recent History
LSE
MTPH
Midatech P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190319 16:39:35